<?xml version="1.0" encoding="UTF-8"?>
<p id="para190">Serum samples were collected at baseline and weeks 1, 2 or 3, 4, 6, 12, 14, 24, 36, and 60. ELISAs developed in-house (assay details in the 
 <xref rid="sec1" ref-type="sec">appendix, p 9</xref>) were done to detect antibodies with binding specificity for the S1 subunit (amino acids 1–725) of MERS coronavirus S (S1-ELISA) and for the full-length S-glycoprotein (full-length-S-ELISA),
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref> reported as end-point titres; positivity cutoffs were the lowest dilutions tested, 100 for S1 and 10 for full-length S ELISA. Serum samples were also assessed for their ability to neutralise MERS coronavirus strain EMC-2012 infection of Vero cells. (
 <xref rid="sec1" ref-type="sec">appendix p 9</xref>). Samples were tested in triplicate for neutralising antibodies and a sample was scored as positive if two of three replicates showed 50% neutralising activity resulting in a geometric mean titre of at least 7·9.
</p>
